Foghorn Therapeutics (NASDAQ:FHTX – Get Rating) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a note issued to investors on Tuesday, Zacks.com reports. According to Zacks, “Foghorn Therapeutics Inc. engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system. Foghorn Therapeutics […]
Wall Street analysts expect Foghorn Therapeutics Inc. (NASDAQ:FHTX – Get Rating) to announce $14.40 million in sales for the current quarter, according to Zacks Investment Research. Two analysts have provided estimates for Foghorn Therapeutics’ earnings, with estimates ranging from $10.00 million to $18.80 million. Foghorn Therapeutics reported sales of $280,000.00 during the same quarter last […]